Use of Infliximab or Adalimumab in Biologic-Naive Patients With Inflammatory Bowel Disease: Study of Patient Reported Outcomes in IBD Partners

被引：0
|
作者：
Weaver, Kimberly [1 ]
Curtis, Jeffrey [2 ]
Beukelman, Tim [2 ]
Zhang, Xian [1 ]
Kappelman, Michael [1 ]
Long, Millie [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2019年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P105
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 50 条
  • [31] TREATMENT DISCONTINUATION, FLARES, AND HOSPITALIZATIONS AMONG BIOLOGIC-NAIVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER THE FIRST YEAR OF TREATMENT: A COMPARATIVE EFFECTIVENESS STUDY OF VEDOLIZUMAB VERSUS INFLIXIMAB
    Raluy, Mireia
    Berger, Ariel
    Khalid, Javaria M.
    Patel, Haridarshan
    GASTROENTEROLOGY, 2018, 154 (06) : S372 - S372
  • [32] Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
    Kamal, Mahmoud E.
    Werida, Rehab H.
    Radwan, Mahasen A.
    Askar, Safaa R.
    Omran, Gamal A.
    El-Mohamdy, Marwa A.
    Hagag, Radwa S.
    INFLAMMOPHARMACOLOGY, 2024, 32 (05) : 3259 - 3269
  • [33] Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients
    Swaminath, A.
    Ullman, T.
    Rosen, M.
    Mayer, L.
    Lichtiger, S.
    Abreu, M. T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (03) : 273 - 278
  • [34] Changes in Patient-Reported Outcomes With Vedolizumab Therapy in Patients With Inflammatory Bowel Diseases (IBD): Results From the IBD Partners Patient Powered Research Network
    Long, Millie D.
    Martin, Christopher F.
    Chen, Wenli
    Luo, Michelle
    CROHNS & COLITIS 360, 2019, 1 (02)
  • [35] Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naive Patients
    Aliyev, Elmar R.
    Hay, Joel W.
    Hwang, Caroline
    PHARMACOTHERAPY, 2019, 39 (02): : 118 - 128
  • [36] Persistence and failure rates of adalimumab monotherapy in biologic-naive patients with psoriasis: A retrospective study
    Reddy, Shivani P.
    Lin, Elaine J.
    Shah, Vidhi V.
    Wu, Jashin J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (03) : 575 - 577
  • [37] Use of the Patient Reported Outcomes Measurement Information System (PROMIS) in a Pediatric Cohort With Inflammatory Bowel Disease (IBD)
    Arvanitis, Marina
    DeWalt, Darren A.
    Martin, Christopher F.
    Long, Millie D.
    Chen, Wenli
    Jaeger, Elizabeth L.
    Goble, Lucy
    Sandler, Robert S.
    Kappelman, Michael
    GASTROENTEROLOGY, 2014, 146 (05) : S26 - S26
  • [38] EDUCATIONAL ACHIEVEMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: AN IBD PARTNERS SURVEY STUDY
    Chreptowicz, Wiktor
    Caldis, Matthew
    Osman, Fauzia
    Long, Millie D.
    Caldera, Freddy
    Saha, Sumona
    GASTROENTEROLOGY, 2023, 164 (06) : S688 - S688
  • [39] Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naive Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
    Bressler, Brian
    Yarur, Andres
    Silverberg, Mark S.
    Bassel, Marielle
    Bellaguarda, Emanuelle
    Fourment, Chris
    Gatopoulou, Anthie
    Karatzas, Pantelis
    Kopylov, Uri
    Michalopoulos, George
    Michopoulos, Spyridon
    Navaneethan, Udayakumar
    Rubin, David T.
    Siffledeen, Jesse
    Singh, Andrew
    Soufleris, Konstantinos
    Stein, Dara
    Demuth, Dirk
    Mantzaris, Gerassimos J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (10): : 1694 - 1706
  • [40] Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study
    Mantzaris, Gerassimos J.
    Bressler, Brian
    Adsul, Shashi
    Luo, Michelle
    Colby, Chris
    Brett, Neil R.
    Saha, Sumit
    Kamble, Pravin
    Wang, Song
    Yarur, Andres
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (03) : 281 - 291
12345